Cargando…

Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function

The optimal regimens of cefmetazole and flomoxef for the treatment of urinary tract infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales are not well defined. Our study found that the pharmacokinetic/pharmacodynamic targets for cefmetazole and flomoxef were 70% T >...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamada, Yukihiro, Kasai, Hidefumi, Suzuki-Ito, Moeko, Matsumura, Yasufumi, Doi, Yohei, Hayakawa, Kayoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027114/ https://www.ncbi.nlm.nih.gov/pubmed/35453208 http://dx.doi.org/10.3390/antibiotics11040456

Ejemplares similares

2778. Retrospective evaluation of effectiveness of Flomoxef for infections due to extended-spectrum β-lactamase-producing Enterobacterales
por: Koizumi, Ryuji, et al.
Publicado: (2023)

Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
por: Horie, Akiyoshi, et al.
Publicado: (2019)

658. Evaluation of Effectiveness of Cefmetazole vs Meropenem for Invasive Urinary Tract Infections Caused by ESBL-Producing Escherichia coli: A Prospective Multicenter Observational Study
por: Hayakawa, Kayoko, et al.
Publicado: (2022)

Pharmacokinetic–pharmacodynamic analysis of cefmetazole against extended-spectrum β-lactamase-producing Enterobacteriaceae in dogs using Monte Carlo Simulation
por: Kusumoto, Mizuki, et al.
Publicado: (2023)

Efficacy and Safety of Cefmetazole for Bacteremia Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales vs Carbapenems: A Retrospective Study
por: Kashihara, Eriko, et al.
Publicado: (2023)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021)

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)

Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
por: Yamashiro, Hidenori, et al.
Publicado: (2023)

A suspicious case of cefmetazole‐induced hypoprothrombinemia
por: Kodama, Nobuhiro, et al.
Publicado: (2017)

A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia
por: Yap, Polly Soo Xi, et al.
Publicado: (2023)

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae
por: Abe, Ryuichiro, et al.
Publicado: (2019)

The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum
por: Goto, Akihiko, et al.
Publicado: (2021)

Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
por: Haba, Yuichiro, et al.
Publicado: (2022)

In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Associated with Urinary Tract Infections in Malaysia
por: Ngoi, Soo Tein, et al.
Publicado: (2021)

Reply: The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum
por: Kang, Cheol-In
Publicado: (2021)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

A Case of Alveolar Bleeding from Clotting Abnormality by Cefmetazole
por: Nakano, Eri, et al.
Publicado: (2019)

Errate: Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
por: Haba, Yuichiro, et al.
Publicado: (2022)

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
por: Ito, Ryota, et al.
Publicado: (2022)

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales
por: Tan, Xing, et al.
Publicado: (2021)

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
por: Darlow, Christopher A., et al.
Publicado: (2022)

Single-Blind, Prospective, Randomized Study of Cefmetazole and Cefoxitin in the Treatment of Postcesarean Endometritis
por: Chatwani, Ashwin, et al.
Publicado: (1995)

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales [Corrigendum]
Publicado: (2021)

New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria
por: Yao, Yancheng, et al.
Publicado: (2022)

Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniae in patients on maintenance hemodialysis
por: Yang, Chih-Chao, et al.
Publicado: (2012)

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
por: O’Donnell, John, et al.
Publicado: (2020)

Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer
por: Tomizawa, Atsushi, et al.
Publicado: (2017)

Pharmacodynamic analysis of hypertension caused by lenvatinib using real‐world postmarketing surveillance data
por: Otani, Yuki, et al.
Publicado: (2021)

Presence of β-Lactamase-producing Enterobacterales and Salmonella Isolates in Marine Mammals
por: Grünzweil, Olivia M., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Comparison of sCIM and Other Phenotypic Detection Methods for Carbapenemase-Producing Enterobacterales
por: Hosoda, Takuya, et al.
Publicado: (2021)

Non-Cytotoxic Nanomaterials Enhance Antimicrobial Activities of Cefmetazole against Multidrug-Resistant Neisseria gonorrhoeae
por: Li, Lan-Hui, et al.
Publicado: (2013)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Plasmid analysis of NDM metallo-β-lactamase-producing Enterobacterales isolated in Vietnam
por: Hirabayashi, Aki, et al.
Publicado: (2021)

Reviving the role of mecillinam against extended spectrum beta-lactamase producing enterobacterales
por: Kaleem, Fatima, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u52gslr00pbh476l5hhldjvgod